Increased serum vascular endothelial growth factor levels in microscopic poly angiitis with pulmonary involvement.

[1]  Claudia Eichler-Jonsson,et al.  Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid , 2005, Oncogene.

[2]  Javier Martín,et al.  A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. , 2005, The Journal of rheumatology.

[3]  F. Quismorio,et al.  Pulmonary involvement in microscopic polyangiitis , 2005, Current opinion in pulmonary medicine.

[4]  K. Tamaki,et al.  Angiogenic cytokines in serum and cutaneous lesions of patients with polyarteritis nodosa. , 2005, Journal of the American Academy of Dermatology.

[5]  D. Scott,et al.  Primary systemic vasculitis: clinical features and mortality. , 2005, QJM : monthly journal of the Association of Physicians.

[6]  P. Sterk,et al.  Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease , 2005, Thorax.

[7]  D. Stewart,et al.  Vascular endothelial growth factor and related molecules in acute lung injury. , 2004, Journal of applied physiology.

[8]  S. Matsumoto,et al.  Thoracic Manifestation of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (MPO-ANCA)-Related Disease: CT Findings in 51 Patients , 2004, Journal of computer assisted tomography.

[9]  K. Arimura,et al.  TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus. , 2004, Blood.

[10]  J. Duncan,et al.  Early neutrophilic expression of vascular endothelial growth factor after traumatic brain injury , 2003, Neuroscience.

[11]  T. Kuijpers,et al.  Involvement of Fcγ receptors and β2 integrins in neutrophil activation by anti‐proteinase‐3 or anti‐myeloperoxidase antibodies , 2003 .

[12]  Y. Kohno,et al.  Prognostic Impact of Vascular Leakage in Acute Kawasaki Disease , 2003, Circulation.

[13]  C. Pusey,et al.  Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  Arthur S Slutsky,et al.  Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. , 2003, American journal of respiratory and critical care medicine.

[15]  A. Nicholson,et al.  Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. , 2003, American journal of respiratory and critical care medicine.

[16]  Chiu-Ching Huang,et al.  Vascular Endothelial Growth Factor 05 Provide Additional Values to C-Reactive Protein and Anti-myeloperoxidase Titer as a Parameter for Evaluating Disease Activity in Anti-myeloperoxidase Associated Vasculitis , 2003, Renal failure.

[17]  D. Thickett,et al.  A role for vascular endothelial growth factor in acute and resolving lung injury. , 2002, American journal of respiratory and critical care medicine.

[18]  K. Arimura,et al.  Purified protein derivative of tuberculin upregulates the expression of vascular endothelial growth factor in T lymphocytes in vitro , 2002, Immunology.

[19]  A. Goldhirsch,et al.  Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  R. Falk,et al.  Microscopic polyangiitis (microscopic polyarteritis). , 2001, Seminars in diagnostic pathology.

[21]  K. Arimura,et al.  Increased serum level of vascular endothelial growth factor in pulmonary tuberculosis. , 2000, American journal of respiratory and critical care medicine.

[22]  B. Housset,et al.  Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[23]  C. Weyand,et al.  Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. , 1999, The American journal of pathology.

[24]  W. Risau,et al.  Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Kumar,et al.  Serum levels of vascular endothelial growth factor (VEGF) are markedly elevated in patients with Wegener's granulomatosis. , 1998, British journal of rheumatology.

[26]  L. Guillevin,et al.  Polyarteritis nodosa, microscopic polyangiitis and Churg–Strauss syndrome , 1998, Lupus.

[27]  G. Karakiulakis,et al.  Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. , 1998, European journal of pharmacology.

[28]  S. Soker,et al.  Inhibition of Vascular Endothelial Growth Factor (VEGF)-induced Endothelial Cell Proliferation by a Peptide Corresponding to the Exon 7-Encoded Domain of VEGF165 * , 1997, The Journal of Biological Chemistry.

[29]  H. Wieland,et al.  Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. , 1997, American journal of respiratory cell and molecular biology.

[30]  Mayumi Ono,et al.  Induction of Vascular Endothelial Growth Factor by Tumor Necrosis Factor α in Human Glioma Cells , 1996, The Journal of Biological Chemistry.

[31]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[32]  R. Moots,et al.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.

[33]  R J Falk,et al.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.

[34]  G. Breier,et al.  Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. , 1992, Development.

[35]  M. Arnaout,et al.  Neutrophil migration across a cultured intestinal epithelium. Dependence on a CD11b/CD18-mediated event and enhanced efficiency in physiological direction. , 1991, The Journal of clinical investigation.

[36]  H. Colten,et al.  Inhibition of phagocytosis of complement C3- or immunoglobulin G-coated particles and of C3bi binding by monoclonal antibodies to a monocyte-granulocyte membrane glycoprotein (Mol). , 1983, The Journal of clinical investigation.

[37]  P. Lamprecht.  TNF-α inhibitors in systemic vasculitides and connective tissue diseases , 2005 .

[38]  E. Kohn,et al.  New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12 , 2004, Angiogenesis.

[39]  S. Mink,et al.  Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. , 2003, Chest.

[40]  H. Kanegane,et al.  Neutrophils and Mononuclear Cells Express Vascular Endothelial Growth Factor in Acute Kawasaki Disease: Its Possible Role in Progression of Coronary Artery Lesions , 2001, Pediatric Research.

[41]  Y. Omori,et al.  Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking. , 1998, Metabolism: clinical and experimental.

[42]  T. Springer,et al.  Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. , 1995, Annual review of physiology.

[43]  R. Winchester,et al.  Surface expression of gp165/95, the complement receptor CR3, as a marker of disease activity in systemic lupus erythematosus , 1988 .

[44]  A. Weiss,et al.  Cell surface molecules and early events involved in human T lymphocyte activation. , 1987, Advances in immunology.